First Pharma Holdings (688197.SH): Kangtatinib Granules included in the new version of the National Medical Insurance Drug Catalog

Zhitong Finance APP news, First Pharma Holdings (688197.SH) announced that, according to the "National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)" (referred to as the "National Medical Insurance Drug Catalog") officially published by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, the company's original innovative product Contetinib Granules (trade name: Shouyaoze) has passed the national medical insurance negotiation and has been included in the new version of the National Medical Insurance Drug Catalog for the first time. The medical insurance payment scope for this drug is: limited to monotherapy for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.